Efficacy and Tolerability of Tricyclic Antidepressants and SSRIs Compared With Placebo for Treatment of Depression in Primary Care: A Meta-Analysis

Sep 29, 2005Annals of family medicine

Effectiveness and side effects of tricyclic antidepressants and SSRIs versus placebo for treating depression in primary care

AI simplified

Abstract

Pooled estimates show a relative risk of 1.37 for improvement with SSRIs compared to placebo.

  • Antidepressants, including tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs), are associated with higher response rates compared to placebo.
  • 56% to 60% of patients responded well to active treatment, while 42% to 47% responded to placebo.
  • The number needed to treat for TCAs is approximately 4, and for SSRIs, it is about 6.
  • The number needed to harm due to withdrawal from side effects ranges from 5 to 11 for TCAs and 21 to 94 for SSRIs.
  • Low-dose TCAs were effective in primary care, marking the first evidence of their efficacy in this setting.

AI simplified

what lands in your inbox each week:

  • πŸ“š7 fresh studies
  • πŸ“plain-language summaries
  • βœ…direct links to original studies
  • πŸ…top journal indicators
  • πŸ“…weekly delivery
  • πŸ§˜β€β™‚οΈalways free